SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is generating significant buzz following its shareholder meeting, where the approval of a substantial increase in authorized shares and a strategic investment in a prominent content creator's company have sparked intense debate. The community is sharply divided, with many expressing concerns over potential dilution and the strategic rationale of the new investment, while others view these moves as a visionary play to expand reach and diversify beyond its core Ethereum holdings. This divergence in opinion, alongside the stock's performance relative to Ethereum, continues to fuel active discussion.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood ($HOOD) is seeing intense conversation following news of indefinitely delayed U.S. crypto legislation, which its CEO suggests negatively impacts American customers and has led to a significant stock decline. This, along with notices of planned future insider share sales, fuels bearish speculation about the company's valuation and near-term price action among some traders. However, a strong bullish contingent points to robust revenue growth and the booming success of prediction markets as key drivers, framing the current dip as a compelling buying opportunity.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings Ltd (SPHL) is trending following an explosive price surge, driven by its ultra-low share float and strong short squeeze potential. The trading community is actively discussing substantial gains and comparing SPHL to other recent high-volatility micro-cap runners, alongside frustrations over some brokers restricting trading activity.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science (MLEC) is trending following its recent 1-for-15 reverse stock split, which created an ultra-low share float. This has ignited significant community discussion and speculation about a potential short squeeze, drawing comparisons to other high-volatility, low-float runners like $SPHL. Despite some frustration over frequent trading halts, investors are actively discussing its potential for substantial upward price movement.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile (ASTS) is soaring to new all-time highs, definitively closing above $100 for the first time, driven by reports of a recent satellite breakthrough. Long-term investors are celebrating this major milestone and anticipating further gains, contrasting sharply with persistent bearish sentiment challenging the pre-revenue valuation and potential need for more capital. Community dialogue highlights the critical need for ASTS's direct-to-cell satellite connectivity, underscored by recent telecom outages, and speculates on upcoming launches and government contract catalysts.

TryHard Holdings Ltd. is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. It operates through the following business segments: Consultancy and management, Event curation, Sub-leasing and Restaurants. The Consultancy and management segment provides expert services to clubs, including operations, event management, and strategic support to enhance performance and engagement. The Event curation segment organize and produce own events, also provides a full suite of services, including event planning, construction, entertainment booking, event operation, and ticket sales. The Sub-Leasing segment acts as an intermediary between landlords and clubs. The Restaurants segment operates several restaurants. The company was founded on October 16, 2013 and is headquartered in Osaka, Japan.

TryHard Holdings Ltd.

TryHard Holdings (THH) is actively trending as a recent IPO with significant volatility, fueled by announcements of a substantial equity purchase facility and a share repurchase program. The community is sharply divided, with many anticipating a major rebound or squeeze due to its low float, while others caution about it being a high-risk pump-and-dump, referencing patterns often seen with similar foreign-based offerings.

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Regentis Biomaterials

Regentis Biomaterials is a trending topic following its recent IPO, with community discussion centered on its extremely low float of 1.25 million shares and a 180-day insider lock-up period, creating a strong short squeeze narrative. Many investors are anticipating significant price action, driven by recent patent news for its GelrinC product and expectations for further company updates.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics (GPCR) is trending after releasing positive Phase 2b data for its oral GLP-1 receptor agonist, aleniglipron, demonstrating significant weight loss. The community is buzzing with speculation about a potential acquisition, especially given recent M&A activity in the competitive obesity drug sector. Investors are weighing the drug's efficacy and tolerability profile against rival therapies as a potential takeover target.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending due to recent significant capital raises, including a $750 million common stock offering and an upsizing of a convertible preferred equity placement to $3 billion led by Apollo. The community views these capital infusions as a clear signal for upcoming large-scale acquisitions, aligning with CEO Brad Jacobs' proven strategy of consolidating fragmented industries. Investors are highly optimistic about Brad Jacobs' M&A playbook and believe these moves will drive substantial long-term growth in the building products distribution sector.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid significant market volatility following its $7.75 billion all-cash acquisition of cybersecurity firm Armis and a notable analyst downgrade, intensifying concerns about AI's impact on the broader software sector. The stock has seen a sharp decline, leading to widespread community debate; many are frustrated by the persistent sell-off, while others view the current valuation as a compelling long-term buying opportunity for a high-quality company strategically positioned to integrate AI. Investors are actively discussing whether the market is overreacting to disruption fears, overlooking ServiceNow's core strengths and its potential to leverage AI for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock...

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat.com reports...

Tectonic Therapeutic (NASDAQ:TECX) Issues Earnings Results, Beats Estimates By $0.03 EPS

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of...

<ul class="summary-bullets"><li>TX45, Tectonic’s experimental Fc-relaxin fusion protein, showed strong improvements in heart and lung function with no serious safety issues in patients with heart failure-related pulmonary hypertension.</li><li>The results expand the drug’s potential reach to a broader patient population with no approved therapies, while the Phase 2 APEX trial continues toward results in 2026.</li><li>Retail investors reacted enthusiastically on Stocktwits, calling the data “unbelievable” and “outstanding.”&nbsp;</li></ul>Shares of Tectonic Therapeutic rose about 30% in after-hours trading on Wednesday after the company reported positive topline results from a Phase 1b Part B clinical trial of TX45, its experimental Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension associated with heart failure with reduced ejection fraction.<h2 class="st-heading-2">TX45 Shows Improvements In Heart And Lung Function</h2>Tectonic said a single intravenous dose of TX45 was well tolerated, with no serious side effects or meaningful changes in blood pressure. The treatment showed clear benefits for heart and lung function by reducing pressure on the heart and lungs and improving blood flow. Key measures, such as pulmonary capillary wedge pressure, total pulmonary resistance, and mean pulmonary artery pressure, all decreased, while cardiac output increased.CEO Alise Reicin said the findings “open up the potential to expand into this additional patient population with significant unmet need and no approved therapies,” adding that the results mirrored those seen in an earlier TX45 study in heart failure with preserved ejection fraction.<h2 class="st-heading-2">Broader Development Plan</h2>The trial enrolled 14 patients and builds on earlier positive data from TX45’s Phase 1b Part A study in ejection fraction. The company is currently running the APEX Phase 2 trial to test TX45 over a 24-week treatment period in patients with ejection fraction, with topline results expected in 2026.Chief Medical Officer Marcella Ruddy said the drug showed “persistent effects at day 29” based on echocardiographic data and continued to demonstrate a favorable safety profile.<h2 class="st-heading-2">Stocktwits Users Cheer Tectonic’s TX45 Results</h2>On Stocktwits, retail sentiment for Tectonic Therapeutic was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the TX45 results as “unbelievable,” predicting the stock could reach $50.&nbsp;<stembedurl>https://stocktwits.com/paddypablo/message/634229088</stembedurl>Another user said the data looked “outstanding,” adding to their position below $22 and expecting the shares to climb further.<stembedurl>https://stocktwits.com/Gurujoe/message/634224719</stembedurl><a href="https://stocktwits.com/symbol/TECX">Tectonic’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tectonic’s stock (TECX) has declined 60% so far in 2025. (Photo credit: Getty Images)

Why Tectonic Therapeutic Stock Soared 30% After-Hours Today

TX45, Tectonic’s experimental Fc-relaxin fusion protein, showed strong improvements in heart and lung function with no serious safety issues in patients with heart failure-related pulmonary hypertension.

Equity

Shares of Tectonic Therapeutic (TECX) soared about 6% in Wednesday’s pre-market after Oppenheimer initiated coverage of the company with an ‘Outperform’ rating.Oppenheimer has an $80 price target on Tectonic, representing an upside of over 380% from the stock’s closing price on Tuesday. The firm stated that it likes the prospects of Tectonic's lead asset, TX45, for addressing prevalent and progressive cardiovascular disorders that are currently inadequately treated.The analyst is optimistic ahead of next year's mid-stage study data readout in pulmonary hypertension with heart failure with preserved ejection fraction, which it believes could pave the way for a multi-billion-dollar global sales opportunity, according to TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TECX">Tectonic</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_7_02_32_AM_png_aa449b866b.webp" alt="TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>Tectonic shares closed down 35% on Tuesday following Eli Lilly's (LLY) data presentation and publication from its failed study in heart failure patients with preserved ejection fraction using a recombinant long-acting relaxin mimetic, Volenrelaxin. Tectonic’s lead candidate also seeks to treat similar cardiovascular disorders.According to Truist analyst Danielle Brill, the negative news "represents another hit to the emerging relaxin class of drugs." Still, the firm also notes that read-through should be limited as the population enrolled in Lilly's trial is distinct from those enrolled in Tectonic's.The firm, which believes Tectonic's approach to targeting Combined Post- and Pre-Capillary Pulmonary Hypertension has "the strongest rationale" and calls the selloff "overdone," maintained a ‘Buy’ rating and a $64 price target on Tectonic shares.TECX stock is down by 64% this year and by about 13% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cybersecurity-vendor-zscaler-s-stock-rises-premarket-what-s-fueling-upside/chwTMR0Rd89">Cybersecurity Vendor Zscaler’s Stock Rises Premarket: What’s Fueling The Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate

Oppenheimer stated that it likes the prospects of Tectonic's lead asset, TX45, to address prevalent and progressive cardiovascular disorders that are inadequately treated.

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Tectonic Therapeutic Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$19.51
Prev Close	$19.67
Open	$19.65
Dividend Yield	0.00%
50-Day Moving Average	$19.66
Beta	1.39
Avg. Volume	321,184.55
PE Ratio	-5.11

52-Week High	$61.07
52-Week Low	$13.70
Market Capitalization	$368.15M
EPS (Annual)	-$6.83
Price to Book	1.38
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TECX
Tectonic Therapeutic Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TECX News

TECXTectonic Therapeutic Inc.